SD Biosensor STANDARD Q COVID-19 IgM/IgG Combo Test Kit (Blood sample) - Box of 40 tests
This kit is a rapid immunochromatography test designed for the qualitative presumptive detection of specific IgM and IgG to 2019 novel coronavirus (nCoV) in humoral fluid.
SD Biosensor STANDARD Q COVID-19 IgM/IgG Combo Test Kit is a rapid immunochromatography test designed for the qualitative presumptive detection of specific IgM and IgG to SARS-CoV-2 in humoral fluid.
- Rapid testing for SARS-CoV-2 antibodies within 10~15 minutes
- Specimen : Whole blood (20ul), serum , plasma (10ul)
- Suitable for Point of Care Testing. No need for extra equipment
- Preferred by healthcare professionals and laboratories
- Made in Korea
Specification:
Information | Detail |
---|---|
Test time | Within 10~15 mins |
Specimen | Whole blood/Serum/plasma |
Storage temperature | 2-30℃/36-86℉ |
SD Biosensor STANDARD Q COVID-19 IgM/IgG Combo Test is a rapid chromatographic immunoassay for the qualitative detection of specific antibodies to SARSCoV- 2 present in human serum, plasma or whole blood. This test is for in vitro professional diagnostic use and intended as an aid to diagnosis of SARS-CoV-2 infection in convalescent phase of patient with clinical symptoms with SARSCoV- 2 infection. It provides only an initial screening test result. More specific alternative diagnosis methods should be performed in order to obtain the confirmation of SARS-CoV-2 infection.
Kit contents:
- Test device (individually in a foil pouch with desiccant)
- Buffer bottle
- Capillary tube (20μl)
- Instructions for use
Kit Storage and Stability:
- Store the kit at room temperature, 2-30°C / 36-86°F, out of direct sunlight.
- Kit materials are stable until the expiration date printed on the outer box.
- Do not freeze the kit.
Test sensitivity:
The seroconversion time of IgM and IgG antibodies varies from person to person, but it was estimated to be around 7 days after onset of symptom. The STANDARD Q COVID-19 IgM/IgG Combo Test showed 94.51% of sensitivity using specimens from patients 7 days after symptom onset (combined IgM+IgG).